Vitex suspends trial for pathogen inactivation system
This article was originally published in Clinica
Executive Summary
VI Technologies (Vitex) has suspended a phase III study of its Inactine blood pathogen inactivation system, after one of the patients in the trial developed an immune response to cells treated with the technology. The company said that pending further evaluation with the US FDA, no additional patients would be recruited to the study. Inactine is designed to inactivate viruses, bacteria and parasites in red blood cells.
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.